SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $RHHBY–Divarasib demonstrated best-in-class efficacy in Phase III trial, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $RHHBY–Divarasib demonstrated best-in-class efficacy in Phase III trial, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer